Literature DB >> 35949855

Esophagogastric junctional neuroendocrine tumor with adenocarcinoma: A case report.

Zhen-Zhen Kong1, Lu Zhang2.   

Abstract

BACKGROUND: At present, cases of esophageal neuroendocrine tumors combined with cardia adenocarcinoma are extremely rare worldwide, and there are no clinical reports. Herein, we describe such a case for clinical reference. CASE
SUMMARY: The presence of cardia cancer and esophageal neuroendocrine tumors in a single patient has not yet been reported. The patient in this case underwent prompt endoscopic treatment and additional surgical resection. Pathology revealed the following: The distance between the cardia cancer and the esophageal neuroendocrine tumors was small, approximately 3 mm. Vascular invasion was observed. The esophageal neuroendocrine tumor was determined to be grade G3. According to the treatment guidelines, after the patient received an explanation of their condition, additional surgical procedures were provided in a timely manner. Early detection and early treatment can successfully prolong survival and improve the quality of life of patients.
CONCLUSION: Early detection and early treatment can successfully prolong survival and improve the quality of life of such patients. ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Cardia moderately differentiated adenocarcinoma; Case report; Endoscopic treatment; Esophageal neuroendocrine tumor; Pathology; Surgery

Year:  2022        PMID: 35949855      PMCID: PMC9254174          DOI: 10.12998/wjcc.v10.i18.6241

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.534


Core Tip: Cases of esophageal neuroendocrine tumors combined with moderately differentiated gastric cardia adenocarcinoma are very rare. Pathology is the gold standard for diagnosis. Endoscopy and additional surgical resection proved to be successful in our case. Early detection and early treatment are both of great significance to the life and health of patients. Considering the successful resection of this case, we provide this case report to serve as a clinical reference.

INTRODUCTION

At present, cases of esophageal neuroendocrine tumors (NETs) combined with cardia adenocarcinoma are extremely rare worldwide. The presence of cardia cancer and esophageal NETs (E-NETs) in a single patient has not yet been reported. Herein, we describe such a case for clinical reference.

CASE PRESENTATION

Chief complaints

A 76-year-old man was hospitalized due to the presence of a cardia mass.

History of present illness

Previous gastroscopy showed a 0-IIa-like cardia lesions and chronic atrophic gastritis with erosions. The pathological examination revealed the following: Tubular adenoma with high-grade intraepithelial neoplasia; mild chronic atrophic gastritis of the antrum; intestinal metaplasia; and Helicobacter pylori infection (Figure 1).
Figure 1

Full abdominal enhanced computed tomography.

Full abdominal enhanced computed tomography.

History of past illness

The patient’s medical history was unremarkable.

Personal and family history

The patient’s personal/family history was unremarkable.

Physical examination

No remarkable characteristics were found during the physical examination.

Laboratory examinations

The laboratory results were all normal.

Imaging examinations

Previous gastroscopy showed a 0-IIa-like lesion of the cardia and chronic atrophic gastritis with erosions. Enhanced computed tomography scan of the full abdomen was performed after hospitalization, which revealed that the local gastric wall of the gastric cardia was slightly thickened, no significantly enlarged lymph node shadow was seen around the cardia, and the rest of the region appeared unchanged (Figures 2-4).
Figure 2

Endoscopic submucosal dissection. A: Cardia mass; B: Submucosal injection; C: Tick to mark the lesion area; D: Lesion specimen.

Figure 4

Pathology of cardia endoscopic submucosal dissection specimens. A: Moderately differentiated adenocarcinoma of the cardia; B: Esophageal neuroendocrine tumors (G3).

Endoscopic submucosal dissection. A: Cardia mass; B: Submucosal injection; C: Tick to mark the lesion area; D: Lesion specimen. Narrow-band imaging. Pathology of cardia endoscopic submucosal dissection specimens. A: Moderately differentiated adenocarcinoma of the cardia; B: Esophageal neuroendocrine tumors (G3).

FINAL DIAGNOSIS

The final diagnosis was differentiated cardia adenocarcinoma and E-NET (G3).

TREATMENT

Endoscopic submucosal dissection and surgical resection were performed.

OUTCOME AND FOLLOW-UP

The patient was in good general condition without obvious discomfort (Figures 5 and 6).
Figure 5

Immunohistochemical staining of esophageal neuroendocrine tumors. A: Syn; B: CD56; C: CgA; D: Ki-67 (25%+).

Figure 6

Representative pathology of excised gastric specimens.

Immunohistochemical staining of esophageal neuroendocrine tumors. A: Syn; B: CD56; C: CgA; D: Ki-67 (25%+). Representative pathology of excised gastric specimens.

DISCUSSION

NENs are a group of highly heterogeneous tumors originating from neuroendocrine cells. They can occur in many parts of the body but are most often found in the digestive system, followed by the lungs. E-NETs are very rare[1], accounting for only 1.4% of all gastrointestinal pancreatic tumors[2] and 0.15%-2.80% of all esophageal tumors[3]. This is due to the poor development of the neuroendocrine system in this area of the body[2]. The incidence rate varies across countries[4]; these tumors are more commonly found in Asian countries than in Western countries[5]. Studies have found that smoking (present in 49%) and drinking (present in 31%) may be a high-risk factor[6,7]. At present, cases of E-NETs combined with cardia adenocarcinoma are extremely rare worldwide, and there are no clinical reports. Pathology is the gold standard for the diagnosis of NETs. The proliferation activity of tumor cells can be evaluated by the number of mitotic figures or the Ki-67 index. According to the 2019 WHO classification standards, NETs are divided into three grades: G1, G2, and G3. The classification criteria are as follows: G1 is defined as < 2 mitotic cells/10 high-power fields (HPFs), G2 as 2-20 cells/10 HPFs, and G3 as > 20 cells/10 HPFs. The Ki-67 index is classified as follows: G1, ≤ 2%; G2, 3%-20%; and G3, > 20%[8]. When the Ki-67 index is inconsistent with the mitotic cell classification, it can instead be classified as high or low. DAXX/ATRX and p53/RB mutations can be used to distinguish G3 NETs from neuroendocrine carcinomas (NECs). According to the guidelines, NETs are < 1 cm in size, are grade G1/G2, have a low metastasis rate (< 3%), and do not infiltrate into the muscularis propria (T1 stage). Thus, they are suitable for endoscopic treatment. For tumors or NECs more than 2 cm in diameter, the metastasis rate can reach as high as 60% to 80%, so radical resection is the first choice.

CONCLUSION

A case of cardia adenocarcinoma combined with E-NETs has not yet been reported. In our patient, after timely endoscopic treatment, pathology revealed that the distance between the cardia cancer and the E-NETs was small, approximately 3 mm, vascular invasion was observed, and the E-NET was determined to be grade G3. According to the treatment guidelines, after the patient received an explanation of their condition, additional surgical procedures were provided in a timely manner. Complete resection of the lesion significantly improved the patient’s quality of life.
  8 in total

1.  Clinicopathological features and outcome of esophageal neuroendocrine tumor: A retrospective multicenter survey by the digestive endoscopy society of Taiwan.

Authors:  I-Chen Wu; Yin-Yi Chu; Yao-Kuang Wang; Cho-Lun Tsai; Jung-Chun Lin; Chao-Hung Kuo; Hsiang-Yao Shih; Chen-Shuan Chung; Ming-Luen Hu; Wei-Chih Sun; Jack P Wang; Hsiu-Po Wang
Journal:  J Formos Med Assoc       Date:  2020-06-27       Impact factor: 3.282

2.  Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases.

Authors:  Qin Huang; Hongyan Wu; Ling Nie; Jiong Shi; Abraham Lebenthal; Jieyu Chen; Qi Sun; Jun Yang; Lily Huang; Qing Ye
Journal:  Am J Surg Pathol       Date:  2013-04       Impact factor: 6.394

3.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.

Authors:  H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge
Journal:  Ann Oncol       Date:  2012-09-11       Impact factor: 32.976

4.  Metastasis of esophageal carcinoma to the brain.

Authors:  Jeffrey S Weinberg; Dima Suki; Fadi Hanbali; Zvi R Cohen; Renato Lenzi; Raymond Sawaya
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860

5.  The 2019 WHO classification of tumours of the digestive system.

Authors:  Iris D Nagtegaal; Robert D Odze; David Klimstra; Valerie Paradis; Massimo Rugge; Peter Schirmacher; Kay M Washington; Fatima Carneiro; Ian A Cree
Journal:  Histopathology       Date:  2019-11-13       Impact factor: 5.087

6.  The clinical features and treatment modality of esophageal neuroendocrine tumors: a multicenter study in Korea.

Authors:  Chang Geun Lee; Yun Jeong Lim; Seun Ja Park; Byung Ik Jang; Seok Reyol Choi; Jae Kwang Kim; Yong-Tae Kim; Joo Young Cho; Chang Hun Yang; Hoon Jai Chun; Si Young Song
Journal:  BMC Cancer       Date:  2014-08-07       Impact factor: 4.430

7.  Neuroendocrine carcinoma of the esophagus: Clinicopathological and immunohistochemical features of 14 cases.

Authors:  Akinori Egashira; Masaru Morita; Reiko Kumagai; Ken-Ichi Taguchi; Masanobu Ueda; Shohei Yamaguchi; Manabu Yamamoto; Kazuhito Minami; Yasuharu Ikeda; Yasushi Toh
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

8.  Esophageal neuroendocrine tumor with initial presentation as painless forehead and neck masses: A case report.

Authors:  Yen-Po Chin; Wei-Fu Lai; Meng-Ting Chiang; Shih-Chieh Chang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.